Coherus BioSciences (CHRS) Misses Q4 EPS by 19c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $0.87 +7.41%
Revenue Growth %: +37.8%
Financial Fact:
Depreciation and amortization: 14.21M
Today's EPS Names:
ATS, SICP, FTCO, More
Revenue Growth %: +37.8%
Financial Fact:
Depreciation and amortization: 14.21M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q4 EPS of $0.53, $0.19 worse than the analyst estimate of $0.72. Revenue for the quarter came in at $123.9 million versus the consensus estimate of $123.01 million.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- H.C. Wainwright Assumes Coherus Biosciences (CHRS) at Buy
- Berkshire Hathaway hits 52-week high on election rally
- CPS Technologies (CPSH) Reports In-Line Q3 EPS
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
